. 2019 Apr 16;10(5):1213–1219. doi: 10.1111/1759-7714.13071

Table 2.

Logistic regression analysis of factors associated with primary resistance and long‐term PFS underlying crizotinib treatment

Risk factor	OR	95% CI	P
Age
< 60 (Reference)	0.87	(0.26–2.85)	0.814
≥ 60	0.87	(0.26–2.85)	0.814
Gender
Male (Reference)	1.27	(0.34–4.67)	0.722
Female	1.27	(0.34–4.67)	0.722
Smoking status
Never smoker (Reference)	0.53	(0.15–1.91)	0.334
Former smoker	0.53	(0.15–1.91)	0.334
ECOG PS
0–1 (Reference)	0.06	(0.01–0.33)	0.001
2–3	0.06	(0.01–0.33)	0.001
Brain metastasis
No (Reference)	0.87	(0.29–2.62)	0.805
Yes	0.87	(0.29–2.62)	0.805
Line of therapy before crizotinib
0 (Reference)	0.60	(0.22–1.61)	0.308
≥ 1	0.60	(0.22–1.61)	0.308

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; OR, odds ratio; PFS, progression‐free survival.